COVID-19 Reinfection

COVID-19 reinfection — testing positive for SARS-CoV-2 after a prior infection — has become increasingly common since the emergence of Omicron in late 2021. Prior to Omicron, reinfection was relatively rare because immunity from original-strain infection provided strong cross-protection. Omicron's extensive mutations in the spike protein allowed it to partially evade that immunity, making reinfection dramatically more common.

Key findings from population-level surveillance:

• The UK Health Security Agency found reinfection rates increased significantly after Omicron BA.1 emerged, with prior-infection protection against Omicron reinfection estimated at only 19% compared to 85%+ for Delta
• A 2022 study in Nature Medicine (Al-Aly et al.) found that reinfected individuals — even those whose initial infections were mild — had elevated risks of adverse health outcomes compared to those infected only once
• The CDC defines a reinfection as a positive test ≥90 days after prior confirmed infection, though positive tests as early as 28 days after recovery can occur

Natural immunity from a COVID-19 infection provides protection, but that protection wanes over time and is variant-dependent:

• Minimum interval: The CDC considers infections within 28 days of each other to be the same episode, not reinfection. Reinfection within 90 days is possible but less common
• Typical pattern: Most reinfections are documented 90 days or more after the prior infection. Protection is generally strongest in the first 3–6 months
• Variant escape: Each new subvariant (XBB, JN.1, KP.2, XEC) introduces mutations that can partially evade immunity from prior Omicron infections, shortening the effective protection window
• Vaccination extends protection: Hybrid immunity — prior infection plus vaccination — provides longer-lasting and broader protection against reinfection than either alone

This is the most important finding about COVID reinfection. Research from the VA St. Louis Health Care System, led by Dr. Ziyad Al-Aly and published in Nature Medicine (2022), analyzed more than 440,000 COVID-19 patients and found:

• Reinfection was associated with increased risk of death, hospitalization, and adverse health outcomes compared to no reinfection — even when the reinfection was mild
• Risk accumulates with each infection. People with two or more infections had higher risk of Long COVID symptoms than those with one infection
• This held true across vaccinated and unvaccinated individuals, though absolute risk was lower in vaccinated people
• Organ systems affected included the lungs, heart, blood, kidneys, diabetes, gastrointestinal tract, musculoskeletal system, and neurological function

The key takeaway: a "mild" reinfection that resolves quickly does not mean zero long-term consequence. Preventing reinfection — through vaccination, good ventilation, and appropriate masking — remains worthwhile even for people who have already had COVID.^[RI1]

The same strategies that reduce initial COVID-19 risk reduce reinfection risk:

• Stay up to date on vaccinations: Updated COVID-19 vaccines targeting current circulating strains provide better protection against reinfection and severe disease. The FDA authorizes updated formulations annually to match the dominant variant
• Improve indoor air quality: SARS-CoV-2 spreads primarily through airborne transmission. HEPA air purifiers significantly reduce viral load in indoor spaces. CO₂ monitors help identify poorly ventilated rooms
• Wear a well-fitting respirator: NIOSH-approved N95 or ASTM-compliant KN95/KF94 masks in high-risk indoor settings substantially reduce exposure. Surgical masks provide less protection against aerosol inhalation
• Test when symptomatic: Confirming infection early allows access to antivirals like Paxlovid, which must be started within 5 days of symptom onset and is associated with lower Long COVID risk